new glp-1 agonist Agonists GLP-1 Receptor Agonists and Research
Description
Berberine and GLP-1 receptor agonists are distinct compounds with different mechanisms of action
Think of your gut like a garden
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain mostbut not allof their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.
A 2026 analysis of 25 products found zero contained semaglutide
